Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
OpenAI Urges US-Led Global Standards for Frontier AI 
China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts 
RBA Says ASX Still Falls Short on Governance and Risk Controls 
US, China Extend Trade Truce to Jan. 10 Ahead of Trump-Xi Summit 
H&M Q3 Profit Beats Estimates as Margins Improve 
Gold Drops Over 1% as Dollar, Treasury Yields Surge on Fed Rate Hike Bets 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
U.S. 10-Year Treasury Yield Hits 2007 High as Fed Rate Hike Bets Rise 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
Oil Prices Surge as U.S.-Iran Diplomacy Hopes Fade 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
CNN, MS NOW and Politico Sue Trump Over White House Media Ban 
South Korea, US Discuss Warship Building Cooperation 
Wall Street Falls as Treasury Yields Surge, Oil Rebounds on Iran Tensions 
SoftBank Launches $11 Billion Bond Sale to Fund OpenAI Investment 
Anthropic’s Claude Discovers CRISPR-Like Enzyme System 
Add as a preferred source on Google
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
